Organization (Industry)
Johnson & Johnson
ClinicalTrials.gov lists Johnson & Johnson as lead sponsor of 1,270 trials, counting the companies grouped under it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 16 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 14 in 2026 and about 11 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 16 already registered with a 2026 start date: at the cutoff, 5 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts. 1 trial is registered to start in 2027 or later.
Logo Johnson & Johnson Services, Inc., via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Johnson & Johnson and 76 companies grouped under it: 1,270 lead-sponsored trials (2 its own, 1,268 in the grouped companies) and 82 legal-entity registrations (12 its own, 70 in the grouped companies).
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Companies grouped under this page (76)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| JOHNSON & JOHNSON VISION CARE, INC. | 221 | 2 |
| Actelion Pharmaceuticals Ltd | 143 | 3 |
| JANSSEN CILAG S.P.A. | 111 | 1 |
| ETHICON, INC. | 67 | 1 |
| Janssen-Cilag International NV | 67 | 0 |
Showing 5 of 76 member companies.
Disease areas (631)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Schizophrenia | 169 |
| Multiple Myeloma | 156 |
| Atrial Fibrillation | 131 |
| Pain | 115 |
| Hypertension, Pulmonary | 101 |
Showing 5 of 631 disease areas.
Trials by start year as sponsor or collaborator (28)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 16 |
| 2025 | 8 |
| 2024 | 4 |
| 2023 | 2 |
| 2022 | 4 |
| 2021 | 4 |
| 2020 | 4 |
| 2019 | 4 |
| 2018 | 5 |
| 2017 | 2 |
Showing 10 of 28 years.
Recruitment duration, a model prediction: none of the 2 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Journals published in (870)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 115 |
| Circulation | 94 |
| Blood | 82 |
| Journal of the American College of Cardiology | 77 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 58 |
Showing 5 of 870 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 18,860 | 3,200 | 2025-12-30 |
SEC-reported annual financials (9)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 94,193,000,000 | 26,804,000,000 | 109,000,000 |
| 2024 | 88,821,000,000 | 14,066,000,000 | 1,841,000,000 |
| 2023 | 85,159,000,000 | 35,153,000,000 | 483,000,000 |
| 2022 | 78,740,000,000 | 20,878,000,000 | 0 |
| 2021 | 82,584,000,000 | 14,714,000,000 | 12,159,000,000 |
| 2019 | 82,059,000,000 | 15,119,000,000 | 11,355,000,000 |
| 2018 | 81,581,000,000 | 15,297,000,000 | 10,775,000,000 |
| 2017 | 76,450,000,000 | 1,300,000,000 | 10,594,000,000 |
| 2016 | not reported | 15,409,000,000 | 9,046,000,000 |
Financing and grant events (33)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-07-27 | Other financing | not disclosed | Sec extracted |
| 2026-02-11 | Debt financing | not disclosed | Edgar offerings |
| 2025-02-26 | Debt financing | not disclosed | Sec extracted |
| 2025-02-21 | Debt financing | 4,174,912,284 | Edgar offerings |
| 2025-02-20 | Debt financing | 5,000,000,000 | Sec extracted |
Showing 5 of 33 events.
FDA recalls (4)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Neutrogena Acne Proofing whipped foam cleanser, (Salicylic Acid 2%), aerosolized product in a can, NET WT. 5 OZ (141 g) , Distributed by Johnson & Johnson Consumer Inc. Skillman, NJ 08558, UPC 0 70501 11131 4 | Class II | 2017-12-07 |
| Neutrogena deep clean purifying whipped foam cleanser, (Salicylic Acid 0.5%), aerosolized product in a can, NET WT. 5 OZ. (141 g) Distributed By: Johnson & Johnson Consumer Inc. Skillman, NJ 08558. UPC: 0 70501 10053 0 | Class II | 2017-12-07 |
| Neutrogena Elevated 4-Holiday Trays (contains Neutrogena Deep Clean Purifying Whipped Foam Cleanser) Case Code: 00070501302866 | Class II | 2017-12-07 |
| Clean & Clear advantage, 3-in-1 foaming wash 8 FL. OZ. (240 mL) bottle, OTC, Distributed in the US by: Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies Inc. Skillman, NJ 08558-9418 NDC 58232-0326-8 | Class III | 2012-12-04 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 9 | 2025-04-11 |
Manufacturing and distribution sites (70)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| ABIOMED, INC. | DANVERS, US | FDA | Abiomed (United States) |
| Janssen Inc | Toronto, CA | Health Canada | Janssen Canada (Canada) |
| JOHNSON & JOHNSON VISION CARE, INC. | Jacksonville, US | FDA | Johnson & Johnson Vision Care (United States) |
| Janssen Biologics B.V. | Leiden, NL | EMA, FDA, Health Canada | Janssen Biologics BV |
| Janssen Cilag SpA | Borgo San Michele, IT | FDA | Janssen Cilag SpA |
Showing 5 of 70 sites.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (295)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Ortho Biotech Products, L.P. | Co sponsors trial with | 19 |
| Ortho-McNeil Neurologics, Inc. | Co sponsors trial with | 12 |
| Bristol Myers Squibb Co | Co sponsors trial with | 7 |
| Government of the United States of America | Co sponsors trial with | 6 |
| Ortho Biotech Clinical Affairs, L.L.C. | Co sponsors trial with | 6 |
Showing 5 of 295 relationships.
Latest dated events (23,170)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2029-12-31 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
| 2029-12-31 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
| 2029-12-31 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
| 2028-01-01 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
| 2028-01-01 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
Showing 5 of 23,170 events.
CLIA clinical laboratory certificates (2)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| JOHNSON AND JOHNSON | Certificate of waiver | Active |
| JOHNSON & JOHNSON | Certificate of waiver | Terminated |
Biomarker capability evidence (168)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACE | Trial collaborator | Named in trial inclusion criteria |
| AGA | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| BTK | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 168 evidence rows.
On Scientist.com
Johnson & Johnson is listed as a research supplier in the Scientist.com network.
Service areas
Momenta is a leader in the analysis, characterization, and design of complex pharmaceutical products. Our scientific foundation is a set of tools and methods that enable one to develop a deep understanding of the links between a compound’s chemical structure, its manufacturing process and its biological function. These innovative tools enable us to develop complex generics and biosimilars as well as facilitate the discovery of novel medicines. We believe that by applying our innovative technology to our discovery and development programs, we have the potential to create a robust pipeline...
Show the full description
Momenta is a leader in the analysis, characterization, and design of complex pharmaceutical products. Our scientific foundation is a set of tools and methods that enable one to develop a deep understanding of the links between a compound’s chemical structure, its manufacturing process and its biological function. These innovative tools enable us to develop complex generics and biosimilars as well as facilitate the discovery of novel medicines. We believe that by applying our innovative technology to our discovery and development programs, we have the potential to create a robust pipeline of innovative generic and novel medicines.
Our success is a result of our committed and talented people. We attract scientists exceptionally skilled in integrating information from diverse technical disciplines and task them with challenging characterization, process, and biology problems. Using this approach, we have designed tools and methods to understand the structure (characterization of chemical components), structure-process (design and control of manufacturing process) and structure-activity (relationships between structure and biological and clinical activity) of complex mixture drugs. From this knowledge comes a diversified product development pipeline consisting of both generic and novel complex mixture drugs designed to address a variety of medical needs.
- Website
- www.momentapharma.com
Not on this page
Checked, with nothing recorded for this organization: active development programs, approved assets, sponsor delivery record, fda warning letters, fda untitled letters, fda inspection record, and biomarkers this organization publishes on.
Work with Momenta Pharmaceuticals on Scientist.com
For prices, more details, or to contact Momenta Pharmaceuticals, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.